The Emergence of Skin Longevity

For decades, anti-aging strategies have dominated the cosmetic landscape. Skincare was developed and positioned as a targeted treatment designed to smooth skin, reduce wrinkles, and lighten brown spots. Marketing terms such as “gentle” exfoliation, collagen “boosting,” and “even” skin tone attracted consumers seeking to counter visible signs of aging. Cosmetic procedures followed suit, while aggressive and now outdated technologies pursued immediate results rather than supporting long-term skin health and structural integrity.

FROM ANTI-AGING TO SKIN LONGEVITY

Today, the concept of anti-aging is fading, along with the promise of quick fixes, in an industry now increasingly focused on regeneration and longevity. The terms “pro-aging” and “well-aging” are now central, emphasizing resilience, renewal, and enhancement of skin function at the cellular level. This approach focuses on improving skin health span by reversing age-related skin dysfunction. "Skinspan," first defined by Wyles et al, refers to the duration that skin maintains optimal function.¹ This includes barrier function, immune competence, regenerative capacity, and aesthetic quality.² Prioritizing skinspan is a strategy that offers a more proactive and positive approach to skin aging.

Dermatology and cosmetic science are increasingly targeting upstream cellular and molecular processes referred to as the hallmarks of aging.³ These include cellular senescence, mitochondrial dysfunction, genomic instability, loss of proteostasis, telomere attrition, dysregulated nutrient sensing, stem cell exhaustion, and altered intercellular communication. Recent updates to the established hallmarks of aging also include chronic inflammation, microbiome dysregulation, diminished mechanical integrity of the extracellular matrix, and deficiencies in autophagy. Although these hallmarks were originally described in the context of systemic aging, studies confirm that they also play a key role in the pathogenesis of skin aging.⁴ These processes modulate extracellular matrix homeostasis, DNA repair, barrier function, skin microbial composition, and skin immunity. Consequently, they influence the phenotype of aging skin, leading to wrinkles, sagging, dyspigmentation, lentigines, xerosis, thinning, delayed wound healing, and increased susceptibility to dermatoses.

ADVANCES IN LONGEVITY-FOCUSED SKINCARE AND INTERVENTIONS

Cosmeceuticals are now being developed to address key drivers of skin aging. These products constitute a new category often referred to as longevity skincare.⁵ Formulators and cosmetic chemists are exploring novel ingredients, including bioactive peptides, growth factors, stem cell technologies, exosomes, and senotherapeutic agents. These actives modify the skin microenvironment by influencing molecular pathways involved in skin aging, including sirtuins, mTOR, NF-κB, TGF-β, and AMPK. Additionally, medications such as rapamycin, rapalogs, and metformin, previously available only in oral formulations, are now being incorporated into topical preparations. These geroprotectors target mTOR and AMPK pathways, and preliminary data suggest potential benefits for aging skin.^6,7

Cosmetic treatments now function as skin health interventions rather than short-term aesthetic corrections. Photobiomodulation, fractional laser resurfacing, microneedling with radiofrequency, platelet-rich plasma (PRP), platelet-rich fibrin matrix (PRFM), exosomes, biostimulatory fillers, and adipose-derived stem cells are integral components of the skin longevity toolkit. These treatments stimulate wound healing, enhance cellular proliferation, promote angiogenesis, and increase collagen production. Furthermore, recent studies demonstrate that energy-based devices, such as fractionated lasers and radiofrequency, may reverse epigenetic markers of aging, effectively reprogramming the skin.² Combining these procedures with longevity-focused cosmeceuticals offers a comprehensive strategy for optimizing skin health.⁸

We are entering a new era of aesthetic medicine; however, several important questions remain. How can meaningful change be measured when outcomes are long term? Should epigenetic clocks be used instead of chronological age? Are biomarkers reliable indicators? Are claims of reversing skin aging scientifically justified? Do such claims contribute to appearance-related anxiety? These and other questions must be addressed. Dermatologists will play a central role in advancing understanding and guiding the responsible application of skin longevity science. This represents a pivotal and exciting time in the evolution of the specialty. 

1. Wyles SP, Maredia HS, Hurt RT, Bonnes SL, Khosla S, LeBrasseur NK, et al. Skinspan: a healthy longevity framework for skin aging. Mayo Clin Proc. 2025;100(11):1976-1991. 

2. Haykal D, Gold M, Lain E, Green J, Farris PK. Reprogramming skin aging: a regenerative and epigenetic perspective on cutaneous longevity. J Cosmet Dermatol. 2026;25(3):e70788. 

3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278. 

4. Jin S, Li K, Zong X, Eun S, Morimoto N, Guo S. Hallmarks of skin aging: update. Aging Dis. 2023;14(6):2167-2176. 

5. Klinngam W, Chaiwichien A, Osotprasit S, Ruktanonchai U, Kanlayavattanakul M, Lourith N, et al. Longevity cosmeceuticals as the next frontier in cosmetic innovation: a scientific framework for substantiating product claims. Front Aging. 2025;6:1586999. 

6. Chung CL, Lawrence I, Hoffman M, et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. Geroscience. 2019;41(6):861-869. 

7. Wyles S, Mehta R, Mannick J, Day D. Skin longevity: a paradigm shift in aesthetics. J Cosmet Dermatol. 2024;23:2814-2815. 

8. Kream E, Fabi SG, Boen M. Skinspan: a holistic roadmap for extending skin longevity with evidence-based interventions. J Cosmet Dermatol. 2025;24(9):e70432.

Patricia Farris, MD

• Board-certified Dermatologist
• Co-founder, Science of Skin Summit
• Clinical Associate Professor, Tulane University School of Medicine  

New Orleans, LA

Ted Lain, MD, MBA, FAAD

• Board-certified Dermatologist
• Co-founder, Science of Skin Summit
• Chief Medical Officer, Sanova Dermatology
• Executive Director, Austin Institute for Clinical Research

 Austin, TX